Evidence-Based Cardiology in Hemodialysis Patients

被引:35
|
作者
Allon, Michael [1 ]
机构
[1] Univ Alabama Birmingham, Div Nephrol, Birmingham, AL 35294 USA
来源
关键词
CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; LEFT-VENTRICULAR HYPERTROPHY; SIROLIMUS-ELUTING STENTS; ALL-CAUSE MORTALITY; QUALITY-OF-LIFE; ATRIAL-FIBRILLATION; CARDIOVASCULAR EVENTS; DIALYSIS PATIENTS; ONLINE HEMODIAFILTRATION;
D O I
10.1681/ASN.2013060632
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cardiac events are the major cause of death in hemodialysis patients. Because of the paucity of randomized clinical trials (RCTs) in hemodialysis patients, most cardiovascular therapies in this population are based on observational studies or results extrapolated from studies that excluded hemodialysis patients. However, associations discovered in observational studies do not prove causality, and these studies often report surrogate outcomes rather than clinical end points. Furthermore, interventions that show effectiveness in the general population may have drastically different outcomes and side effect profiles in hemodialysis patients. This review discusses the results of RCTs undertaken recently to evaluate cardiovascular therapies in hemodialysis patients and emphasizes clinically relevant outcomes. Although some interventions have produced similar outcomes in hemodialysis patients and the general population, others have not, suggesting that the management of cardiovascular disease in hemodialysis patients may require strategies that differ from the best practice guidelines applied to general population.
引用
收藏
页码:1934 / 1943
页数:10
相关论文
共 50 条